Geneviève Crombag1,2, Raf van Hoof1, Floris Schreuder3, Martine Truijman4, Sylvia Heeneman5, Paul Nederkoorn6, Werner Mess2,7, Robert van Oostenbrugge2,4, Jan-Willem Daemen8, Mat Daemen9, Joachim Wildberger1,2, and Eline Kooi1,2
1Radiology & Nuclear Medicine, Maastricht University Medical Center, Maastricht, Netherlands, 2Cardiovascular Research Institute Maastricht, Maastricht, Netherlands, 3Department of Neurology & Donders Institute for Brain Cognition & Behaviour, Radboud University Medical Centre, Nijmegen, Netherlands, 4Neurology, Maastricht University Medical Center, Maastricht, Netherlands, 5Pathology, Maastricht University Medical Center, MAastricht, Netherlands, 6Neurology, Amsterdam Medical Center, Amsterdam, Netherlands, 7Clinical Neurophysiology, Maastricht University Medical Center, Maastricht, Netherlands, 8Surgery, Maastricht University Medical Center, Maastricht, Netherlands, 9Pathology, Amsterdam Medical Center, Amsterdam, Netherlands
Synopsis
The
presence of intraplaque haemorrhage (IPH) has been related to plaque rupture,
plaque progression, and predicts cerebrovascular events. However, the mechanisms
leading to IPH are not fully understood. The dominant view is that IPH is
caused by leakage of erythrocytes from immature microvessels.
101 patients underwent MRI of the symptomatic carotid plaque for detection of
IPH and dynamic contrast-enhanced MRI for assessment of plaque
microvasculature.
A decreased vessel wall Ktrans was found for IPH positive patients.
No difference in adventitial Ktrans was found in patients with and
without IPH.
Not only leaky plaque microvessels, but additional factors may contribute to
IPH development.
Introduction
Rupture of a vulnerable
atherosclerotic plaque is likely to be an important cause of clinical ischemic
events such as stroke or myocardial infarction (1). The presence of intraplaque
haemorrhage (IPH) has been related to plaque rupture, is associated with plaque
progression, and predicts cerebrovascular events. However, the mechanisms
leading to IPH are not fully understood. The dominant view is that IPH is
caused by leakage of erythrocytes from immature microvessels. The aim of the
present study was to investigate whether there is an association between
atherosclerotic plaque microvasculature and presence of IPH in a relatively
large prospective cohort study of patients with symptomatic carotid plaque.
Materials & Methods
101 symptomatic patients with ≥2mm carotid
plaque underwent 3T MRI scanning (Achieva, Philips Healthcare, Best, The Netherlands)
using a dedicated 8-channel carotid RF coil (Shanghai Chenguan Medical Technologies
Co., Shanghai, China). A T1weighted (T1w) inversion recovery turbo field echo
(IR-TFE) sequence was used for detection of IPH. An end diastolic ECG-gated 3D T1-TFE dynamic
contrast MR imaging was used for the assessment of plaque microvasculature. The
temporal resolution was ~20 seconds/time
frame (dependent on heart rate). At the beginning of the third time frame, 0.1
mmol/kg of a small molecular contrast medium Gadobutrol (Gadovist, Bayer HealthCare,
Berlin, Germany), was injected with a power injector (Spectris Solaris, Medrad,
Warrendale, PA, USA) at 0.5 ml/sec followed by a 20 ml saline flush at the same
rate. DCE-MRI acquisition was continued for six minutes after contrast
injection. Ktrans, an indicator of microvascular flow, density and
leakiness, was estimated using pharmacokinetic modeling (Patlak model) in the
vessel wall and adventitia. The entire vessel wall region is defined as the
region between the luminal and outer wall contours. The adventitial region of
the vessel wall was delineated according to previously described criteria, i.e.
all pixels within 0.625 mm of the outer wall contour in a region of the vessel
wall with plaque (defined as having a wall thickness >1.5 mm) (2). Statistical
analysis was performed using an independent samples T-test and logistic
regression, correcting for clinical risk factors.
Results
A decreased vessel wall Ktrans was
found for IPH positive patients (0.033±0.001 min-1
versus 0.040±0.001, p=0.001; Figure 3), which remained significant after correction for
clinical risk factors associated with IPH or Ktrans (Table 1). No difference in adventitial Ktrans was found in patients
with and without IPH (0.040±0.002 versus 0.039±0.001 min-1).Discussion
We did
not find a positive association between (leaky) microvasculature (Ktrans)
and IPH. We found lower median Ktrans values in the entire vessel
wall in patients with IPH. This may be related to a larger amount of necrotic
tissue in plaques with IPH. Indeed a significant, negative Pearson’s
correlation coefficient (ρ=-0.26, p<0.01) was found for median vessel wall Ktrans
with the volume % of the lipid-rich necrotic core (LRNC).
Our findings are in contrast to the dominant view that IPH is mainly caused by
leakage of erythrocytes of plaque microvasculature. Alternatively, disruptions
of the fibrous cap (e.g. plaque fissures or plaque rupture) can lead to IPH (4). A histopathological study (5) showed that fibrous cap fissures were frequently accompanied by
IPH. In line with the concept that IPH can also originate from fibrous cap
disruption, it was recently shown that the presence of intraplaque haemorrhage
is associated with a disruption of the atherosclerotic plaque surface (plaque
ulceration and/or a fissured fibrous cap) in patients with a mild to moderate
carotid stenosis (6).Conclusion
A reduced vessel wall Ktrans is
associated with the presence of IPH, independent of clinical risk factors,
while no difference in adventitial Ktrans was found in plaques with
and without IPH. Thus, we could not confirm a positive association between
plaque microvasculature and IPH several weeks after a cerebrovascular event.
Not only leaky plaque microvessels, but additional factors may contribute to
IPH development.Acknowledgements
Acknowledgements:
The
authors thank R.J. van der Geest (Department of Radiology, Leiden University
Medical Center, Leiden, The Netherlands) for providing the VesselMASS analysis
software package.
Sources of Funding:
This research was performed within the framework of CTMM, the Center for
Translational Molecular Medicine (www.ctmm.nl), project PARISk (grant 01C-202),
and supported by the Dutch Heart Foundation.
This project has
received funding from the European Union (EU) Horizon 2020 research and
innovation programme under the Marie Skłodowska-Curie grant agreement No 722609.”
J.E. Wildberger and M.E. Kooi are supported by Stichting de Weijerhorst.
Disclosures:
None.
References
1. Bentzon
JF et al. Circ Res. 2014;114(12):1852-66.
2. Sun J et al. Stroke.
2013;44(4):1031-6.
3. Virmani R et al.
Arterioscler Thromb Vasc Biol. 2005;25(10):2054-61.
4. Falk E. Br Heart J.
1983;50(2):127-34.
5. Constantinides P. Journal
of Atherosclerosis Research. 1966;6(1):1-17.
6. van Dijk AC et al. AJNR Am
J Neuroradiol. 2015;36(11):2127-33.